Vβ17 T‐Cell Receptor Peptide Vaccine

Moreland, Larry W.; Heck, Louis W.; Koopman, William J.; Saway, P A; Adamson, T. C.; Fronek, Zdenka; O’Connor, Richard D.; Morgan, Elizabeth E.; Diveley, J. P.; Chieffo, Nicole; Freeman, T. D.; Richieri, S. R.; Carlo, Dennis J.; Brostoff, Steven W.

doi:10.1111/j.1749-6632.1995.tb44514.x

Cited by 11 publications

(4 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TCR peptide vaccination has also been used instead of whole-cell immunization. A TCR peptide, the BV17 TCR, was used for the immunization of RA patients and a phase I open label study showed a decrease in joint scores; in addition, the peptide was well tolerated [80]. Another placebo-controlled trial using a combination of BV3, BV14 and BV17 TCR peptides, showed clinical improvement with no adverse or toxic effects [81,82].…”

Section: Peptides In Ramentioning

confidence: 99%

“…Delayed the onset of proteinuria in pre-autoimmune mice, prolonged survival and stopped progression of nephritis in diseased mice [203][204][205][206] H2A ( Recognized by T-cell clones generated from SLE patients [211] SmB (16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33) SmB (64)(65)(66)(67)(68)(69)(70)(71)(72)(73)(74)(75)(76)(77)(78)(79)(80)(81) SmB (136)(137)(138)(139)(140)(141)(142)(143)(144)...…”

Section: Peptides In Msmentioning

confidence: 99%

See 1 more Smart Citation

Advances in the Treatment of Autoimmune Diseases; Cellular Activity, Type-1/Type-2 Cytokine Secretion Patterns and their Modulation by Therapeutic Peptides

Mouzaki¹,

Deraos²,

Chatzantoni

2005

CMC

View full text Add to dashboard Cite

Autoimmune diseases are many, have an overall prevalence of about 3% of the world population, affecting more women than men, and their incidence is influenced by genetics and the environment. It is currently thought that the immune response of a genetically predisposed individual to an environmental pathogen, under the influence of inadequate or non-functional immunoregulatory mechanisms, can lead to the development of an autoimmune disease. Advances in the treatment of autoimmune diseases follow a better understanding of the abnormalities in the cellular activity pathways and the resulting, often permanent, imbalance of the pro- and anti-inflammatory cytokine expression profiles. Over the past few years, there has been a dramatic change in the therapeutic regimens employed in autoimmune diseases, with soluble receptors, monoclonal antibodies and molecular mimetics enhancing or gradually replacing conventional immunosuppressive therapies. New biologicals have been developed, targeting defined pathways of the adaptive immune response. One approach towards the therapeutic management of autoimmune diseases involves the design and use of peptide analogs of disease-associated epitopes to be used as immunomodulatory drugs. Peptides can target cell-functions directly, by interfering with the formation of the tri-molecular complex MHC-Peptide-TCR, and/or they can target soluble mediators such as cytokines or their receptors, eventually replacing monoclonal antibody therapies. This review offers an update on the treatment modalities of certain prototypic autoimmune diseases, based on the current knowledge of disease pathogenesis, with emphasis on cell activation and cytokine expression profiles.

show abstract

Section: Peptides In Ramentioning

confidence: 99%

Section: Peptides In Msmentioning

confidence: 99%

Advances in the Treatment of Autoimmune Diseases; Cellular Activity, Type-1/Type-2 Cytokine Secretion Patterns and their Modulation by Therapeutic Peptides

Mouzaki¹,

Deraos²,

Chatzantoni

2005

CMC

View full text Add to dashboard Cite

show abstract

“…Apart from peptides from self-antigens, those from T-cell receptor (TCR) also have been explored as therapeutic vaccines to treat autoimmune diseases including rheumatic diseases, which may be mediated by their roles in modulating autoreactive T cells or activating Tregs [96][97][98][99]. Some studies have provided encouraging findings regarding the safety and the efficacy of TCR peptide-based therapeutic vaccines in patients with rheumatic diseases [96]. However, the molecular mechanisms underlying the therapeutic roles of TCR peptide-based vaccines are still not clearly defined and further studies are needed on this aspect.…”

Section: Journal Of Immunology Researchmentioning

confidence: 99%

“…Some studies using animal models of RA found that vaccination with TCR V beta chain peptides could prevent CIA by inhibiting pathogenic T cells [152]. Some clinical studies also have provided encouraging findings regarding the safety and the efficacy of TCR peptide-based therapeutic vaccines in RA patients [96,153]. A placebo-controlled trial reported by Moreland et al found that vaccination with a combination of Vbeta3, Vbeta14, and Vbeta17 TCR peptides was well tolerated and was effective in RA patients [153].…”

Section: Journal Of Immunology Researchmentioning

confidence: 99%

Peptide-Based Vaccination Therapy for Rheumatic Diseases

Wang

Chen

Zheng

et al. 2020

Journal of Immunology Research

View full text Add to dashboard Cite

Rheumatic diseases are extremely heterogeneous diseases with substantial risks of morbidity and mortality, and there is a pressing need in developing more safe and cost-effective treatment strategies. Peptide-based vaccination is a highly desirable strategy in treating noninfection diseases, such as cancer and autoimmune diseases, and has gained increasing attentions. This review is aimed at providing a brief overview of the recent advances in peptide-based vaccination therapy for rheumatic diseases. Tremendous efforts have been made to develop effective peptide-based vaccinations against rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), while studies in other rheumatic diseases are still limited. Peptide-based active vaccination against pathogenic cytokines such as TNF-α and interferon-α (IFN-α) is shown to be promising in treating RA or SLE. Moreover, peptide-based tolerogenic vaccinations also have encouraging results in treating RA or SLE. However, most studies available now have been mainly based on animal models, while evidence from clinical studies is still lacking. The translation of these advances from experimental studies into clinical therapy remains impeded by some obstacles such as species difference in immunity, disease heterogeneity, and lack of safe delivery carriers or adjuvants. Nevertheless, advances in high-throughput technology, bioinformatics, and nanotechnology may help overcome these impediments and facilitate the successful development of peptide-based vaccination therapy for rheumatic diseases.

show abstract

T Cell Receptor Peptide Vaccines as Immunotherapy

Sw¹

1995

Inflammation: Mechanisms and Therapeutics

View full text Add to dashboard Cite

Vβ17 T‐Cell Receptor Peptide Vaccine

Cited by 11 publications

References 2 publications

Advances in the Treatment of Autoimmune Diseases; Cellular Activity, Type-1/Type-2 Cytokine Secretion Patterns and their Modulation by Therapeutic Peptides

Advances in the Treatment of Autoimmune Diseases; Cellular Activity, Type-1/Type-2 Cytokine Secretion Patterns and their Modulation by Therapeutic Peptides

Peptide-Based Vaccination Therapy for Rheumatic Diseases

T Cell Receptor Peptide Vaccines as Immunotherapy

Contact Info

Product

Resources

About